Financing, Equity Capital Markets

Fate Therapeutics, Inc.

09/18
|
$143.8 Million
Piper Sandler served as bookrunner for Fate Therapeutics, Inc. on a confidentially marketed follow-on offering
Sub-Type
CMFO
Sub-Sector
Biopharma